Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023)

SAB Biotherapeutics (SABS) has disclosed Convertible Debt for 2 consecutive years, with $541644.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Convertible Debt changed N/A year-over-year to $541644.0, compared with a TTM value of $541644.0 through Jun 2023, changed N/A, and an annual FY2022 reading of $541644.0, changed N/A over the prior year.
  • Convertible Debt was $541644.0 for Q2 2023 at SAB Biotherapeutics, roughly flat from $541644.0 in the prior quarter.
  • Across five years, Convertible Debt topped out at $541644.0 in Q4 2022 and bottomed at $541644.0 in Q4 2022.